68 related articles for article (PubMed ID: 27680564)
1. Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.
Buta C; Benabou E; Lequoy M; Régnault H; Wendum D; Merabtene F; Chettouh H; Aoudjehane L; Conti F; Chrétien Y; Scatton O; Rosmorduc O; Praz F; Fartoux L; Desbois-Mouthon C
J Exp Clin Cancer Res; 2016 Sep; 35(1):154. PubMed ID: 27680564
[No Abstract] [Full Text] [Related]
2. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
[TBL] [Abstract][Full Text] [Related]
3. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K
Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma.
van der Horst EH; Weber I; Ullrich A
Int J Cancer; 2005 Feb; 113(5):689-98. PubMed ID: 15499613
[TBL] [Abstract][Full Text] [Related]
5. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
6. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation.
De Potter IY; Poumay Y; Squillace KA; Pittelkow MR
Exp Cell Res; 2001 Dec; 271(2):315-28. PubMed ID: 11716544
[TBL] [Abstract][Full Text] [Related]
7. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
9. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS
Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991
[TBL] [Abstract][Full Text] [Related]
10. Differential signaling by an anti-p185(HER2) antibody and heregulin.
Le XF; Vadlamudi R; McWatters A; Bae DS; Mills GB; Kumar R; Bast RC
Cancer Res; 2000 Jul; 60(13):3522-31. PubMed ID: 10910064
[TBL] [Abstract][Full Text] [Related]
11. Forskolin increases neuregulin receptors in human Schwann cells without increasing receptor mRNA.
Fregien NL; White LA; Bunge MB; Wood PM
Glia; 2005 Jan; 49(1):24-35. PubMed ID: 15390106
[TBL] [Abstract][Full Text] [Related]
12. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation.
Stove C; Stove V; Derycke L; Van Marck V; Mareel M; Bracke M
J Invest Dermatol; 2003 Oct; 121(4):802-12. PubMed ID: 14632199
[TBL] [Abstract][Full Text] [Related]
13. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A
J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520
[TBL] [Abstract][Full Text] [Related]
14. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
15. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Zhou BB; Peyton M; He B; Liu C; Girard L; Caudler E; Lo Y; Baribaud F; Mikami I; Reguart N; Yang G; Li Y; Yao W; Vaddi K; Gazdar AF; Friedman SM; Jablons DM; Newton RC; Fridman JS; Minna JD; Scherle PA
Cancer Cell; 2006 Jul; 10(1):39-50. PubMed ID: 16843264
[TBL] [Abstract][Full Text] [Related]
16. Involvement of heregulin/HER3 in the primary culture of human urothelial cancer.
Okuyama H; Yoshida T; Endo H; Nakayama M; Nonomura N; Nishimura K; Inoue M
J Urol; 2013 Jul; 190(1):302-10. PubMed ID: 23313199
[TBL] [Abstract][Full Text] [Related]
17. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP
Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
[TBL] [Abstract][Full Text] [Related]
18. gamma-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line.
Wang XZ; Jolicoeur EM; Conte N; Chaffanet M; Zhang Y; Mozziconacci MJ; Feiner H; Birnbaum D; Pébusque MJ; Ron D
Oncogene; 1999 Oct; 18(41):5718-21. PubMed ID: 10523851
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.
Le XF; McWatters A; Wiener J; Wu JY; Mills GB; Bast RC
Clin Cancer Res; 2000 Jan; 6(1):260-70. PubMed ID: 10656457
[TBL] [Abstract][Full Text] [Related]
20. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
Shi X; Xu L; Yu J; Fang X
Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
